Abbott Gets a Stent--But What Else?
Abbott Laboratories has licensed US co-promotion rights to Biocompatibles International's coated stents and certain other interventional vascular products. Abbott already made a bold entry into cardiovascular devices when it bought Perclose Inc., the leader in arterial closure devices. What's next? Perhaps it could buy Boston Scientific, whose full product line would instantly propel Abbott to the top of the interventional cardiology market.
You may also be interested in...
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."
BioMedican is ready to produce CBG, cannabigerol, and THC-V, tetrahydrocannabivarin, through biosynthesis and plans by the end of the year to start making CBN, cannabinol, and THC-A, tetrahydrocannabinolic-acid.